Cellular Repair: How Peptides Support Healthy Aging

What makes GHK-Cu remarkable: It is one of the very few longevity peptides with a documented age-related decline in human plasma, confirmed gene expression data, and multiple human studies — making it substantially better-evidenced than most compounds in this space. Its plasma levels drop by approximately 60% from young adulthood to age 60, mirroring the same trajectory seen with NAD+.

Preclinical research has shown GHK-Cu upregulates over 4,000 genes associated with tissue repair — an unusually broad genomic influence for a single small molecule. Its mechanisms include stimulating collagen synthesis and cross-linking, inhibiting NF-κB (the master inflammatory regulator), activating antioxidant gene expression, and promoting angiogenesis and wound healing. In aged human fibroblast studies, GHK-Cu restored gene expression patterns toward those of younger cells — a finding that has significant implications for the epigenetic hallmark of aging.^[2]

Evidence in humans: The most robust human data is for topical and wound healing applications — GHK-Cu is one of the most studied ingredients in clinical dermatology for collagen synthesis, skin repair, and wound healing. For systemic anti-aging applications via injection, the evidence base is less developed. The genomic and anti-inflammatory mechanisms are well-characterised; the clinical translation to measurable aging endpoints in otherwise healthy humans awaits larger trials.

The exercise-mimicking mechanism: MOTS-c is encoded in mitochondrial DNA — an unusual origin that distinguishes it from most other peptides and gives it particular relevance to mitochondrial aging. Its primary action is activating AMPK (AMP-activated protein kinase), sometimes called the cell's "energy sensor" — the same enzyme activated by exercise, caloric restriction, and metformin.

AMPK activation promotes fatty acid oxidation, improves insulin sensitivity, stimulates mitochondrial biogenesis (the production of new mitochondria), and inhibits mTOR — a nutrient sensing pathway that when chronically overactive accelerates aging. In preclinical models, MOTS-c administration produces effects that functionally resemble exercise: improved glucose metabolism, reduced fat accumulation, and better mitochondrial function. 2023–2024 mouse studies documented extended lifespan in aged subjects following chronic MOTS-c administration — data that, while promising, requires replication and human translation.^[3]

Honest assessment: MOTS-c is a compelling early-stage longevity compound with a sound mechanistic foundation, documented age-related decline in humans, and lifespan extension data in aged mice. Human clinical trial data is minimal. It is among the most scientifically interesting peptides in the longevity space — and among those where the distance between current evidence and proven human benefit is significant.

Why SS-31 matters to the broader longevity conversation: SS-31's 2024 FDA approval for Barth syndrome — a rare genetic disorder of mitochondrial function — is significant beyond its specific indication. It validates two things: first, that a small peptide can effectively target and improve mitochondrial function in humans; second, that this class of compound has a documented human safety profile. Before this approval, mitochondrial targeting with peptides was primarily a preclinical concept.

SS-31 stabilises cardiolipin — a lipid critical to the inner mitochondrial membrane structure — and reduces reactive oxygen species production at the source. Since mitochondrial dysfunction is one of the most universally implicated hallmarks of aging (affecting muscle, brain, cardiovascular, and metabolic function simultaneously), the proof that mitochondrial peptide therapy is pharmacologically viable in humans is scientifically important — even though the aging application is not yet FDA-indicated.^[4]

The selectivity mechanism: Senescent cells are uniquely dependent on the FOXO4-p53 interaction for their survival. When FOXO4 binds to p53 in the nucleus of a senescent cell, it prevents p53 from triggering apoptosis — allowing the cell to persist and secrete SASP. FOXO4-DRI is a modified version of the FOXO4 peptide that competes with this interaction, freeing p53 to trigger programmed death specifically in the senescent cells that depend on this pathway. Healthy cells, which are not FOXO4-p53 dependent in the same way, are not affected.

The 2017 Nature Medicine paper that established FOXO4-DRI produced dramatic results in aged mice — restored hair density, fitness, and kidney function, with selective elimination of senescent cells. This remains one of the most impactful single papers in peptide senolytic research, and has driven significant interest in the concept of "senolytic therapy."

Where the evidence stands: FOXO4-DRI is a compelling mechanistic story with strong animal data and a sound cellular rationale. Human evidence is minimal. The practical challenge is that senescent cells are heterogeneous — different cell types may require different senolytics — and the optimal timing, dose, and frequency for human use are entirely unknown. It represents some of the most exciting early-stage work in longevity science while remaining genuinely experimental in humans.